Daxor Corporation Common Stock
DXR
DXR: Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
moreShow DXR Financials
Recent trades of DXR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by DXR's directors and management
Government lobbying spending instances
-
$20,000 Jan 20, 2023 Issue: Defense
-
$10,000 Oct 17, 2022 Issue: Defense
-
$30,000 Jul 19, 2022 Issue: Defense
-
$20,000 Oct 12, 2017 Issue: Defense Veterans
-
$10,000 Jul 14, 2017 Issue: Veterans Defense
-
$10,000 Apr 19, 2017 Issue: Defense Veterans
New patents grants
-
Patent Title: Blood volume analysis with volume-aware blood component measures and treatment Dec. 21, 2021
-
Patent Title: Automated blood analyzer Apr. 07, 2015
-
Patent Title: Automated total body albumin analyzer Apr. 07, 2015
Federal grants, loans, and purchases
Followers on DXR's company Twitter account
Number of mentions of DXR in WallStreetBets Daily Discussion
Recent insights relating to DXR
Recent picks made for DXR stock on CNBC
ETFs with the largest estimated holdings in DXR
Flights by private jets registered to DXR